<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT01346982</url>
  </required_header>
  <id_info>
    <org_study_id>SILIDAR</org_study_id>
    <secondary_id>2010-021159-25</secondary_id>
    <nct_id>NCT01346982</nct_id>
  </id_info>
  <brief_title>Drug Interactions Between Silimarine and Darunavir/Ritonavir</brief_title>
  <official_title>Drug Interactions Between Silimarine And Darunavir/Ritonavir</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Fundacio Lluita Contra la SIDA</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>IrsiCaixa</agency>
      <agency_class>Other</agency_class>
    </collaborator>
    <collaborator>
      <agency>Fundaci√≥ Institut de Recerca de l'Hospital de la Santa Creu i Sant Pau</agency>
      <agency_class>Other</agency_class>
    </collaborator>
  </sponsors>
  <source>Fundacio Lluita Contra la SIDA</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      This is a clinical trial to characterize drug interactions between silimarine and the
      protease inhibitor darunavir/ritonavir.
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      The silimarine is the main component of milk thistle (Sylibum marianum), a medicinal herb
      which, due to its attributed hepatoprotective properties, is widely used by HIV infected
      patients

      15 patients on stable antiretroviral therapy including darunavir/ritonavir 600/100 mg twice a
      day during four weeks will be enrolled. After their inclusion in the study, patients will
      receive treatment with silimarine (150 mg every 8 hours) from day 1 until two weeks later
      (day 14). On days 0 and 14, blood samples will be drawn immediately before and 1, 2, 4, 6, 8,
      10 and 12 hours after the administration of darunavir/ritonavir, and darunavir and ritonavir
      concentrations in plasma will be determined by high performance liquid chromatography using a
      validated method.
    </textblock>
  </detailed_description>
  <overall_status>Completed</overall_status>
  <start_date>March 2011</start_date>
  <completion_date type="Actual">July 2011</completion_date>
  <primary_completion_date type="Actual">July 2011</primary_completion_date>
  <phase>Phase 4</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Non-Randomized</allocation>
    <intervention_model>Single Group Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Area under the plasma concentration-time curve during the dosing interval (AUC0-12) of darunavir</measure>
    <time_frame>DAY 0, day 14</time_frame>
  </primary_outcome>
  <secondary_outcome>
    <measure>Area under the plasma concentration-time curve during the dosing interval (AUC0-12) of ritonavir</measure>
    <time_frame>DAY 0, day 14</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Darunavir and ritonavir clearance (CL/F)</measure>
    <time_frame>DAY 0, day 14</time_frame>
    <description>Change from day 0 in Darunavir and ritonavir clearance at day 14</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Darunavir and ritonavir volume of distribution (V/F)</measure>
    <time_frame>DAY 0, day 14</time_frame>
    <description>Change from day 0 in Darunavir and ritonavir volume of distribution at day 14</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Darunavir and ritonavir elimination half-life (t1/2) of darunavir and ritonavir</measure>
    <time_frame>DAY 0, day 14</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Darunavir and ritonavir trough concentration in plasma</measure>
    <time_frame>DAY 0, day 14</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Adverse events and laboratory abnormalities</measure>
    <time_frame>DAY 0, 14, 28</time_frame>
    <description>Number of patients with adverse events and laboratory abnormalities grade 3 or 4</description>
  </secondary_outcome>
  <number_of_arms>1</number_of_arms>
  <enrollment type="Anticipated">15</enrollment>
  <condition>HIV</condition>
  <arm_group>
    <arm_group_label>Silimarine</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>darunavir + ritonavir + silimarine</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Silimarine</intervention_name>
    <description>darunavir/ritonavir 600/100 mg + silimarine (150 mg every 8 hours)</description>
    <arm_group_label>Silimarine</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Patients receiving antiretroviral therapy containing darunavir / ritonavir at the
             approved dose of 600/100 mg twice daily for at least 4 weeks

          -  HIV viral load in plasma &lt;50 copies / mL

          -  Absence of acute infections and / or tumors in the three months prior to inclusion.

          -  Subject able to follow the treatment period, without suspicion of poor adherence in
             previous antiretroviral treatments.

        Exclusion Criteria:

          -  Any clinical or historical observation that could interfere with the pharmacokinetics
             of medications, such as gastrointestinal illness or surgery (except for herniotomy and
             appendectomy), changes in the composition of plasma proteins, some indication of
             hepatic or renal dysfunction.

          -  Active alcohol consumption (&gt; 50 g / day) or illicit drugs (except cannabis).
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <location>
    <facility>
      <name>Lluita contra la Sida Foundation, HIV Unit</name>
      <address>
        <city>Badalona</city>
        <state>Barcelona</state>
        <zip>08916</zip>
        <country>Spain</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>Spain</country>
  </location_countries>
  <verification_date>September 2011</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>April 18, 2011</study_first_submitted>
  <study_first_submitted_qc>May 3, 2011</study_first_submitted_qc>
  <study_first_posted type="Estimate">May 4, 2011</study_first_posted>
  <last_update_submitted>September 29, 2011</last_update_submitted>
  <last_update_submitted_qc>September 29, 2011</last_update_submitted_qc>
  <last_update_posted type="Estimate">September 30, 2011</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>Darunavir</keyword>
  <keyword>Silimarine</keyword>
  <keyword>interaction</keyword>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Ritonavir</mesh_term>
    <mesh_term>Darunavir</mesh_term>
  </intervention_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

